Target Name: VASH2
NCBI ID: G79805
Other Name(s): Vasohibin 2, transcript variant 4 | VASH2_HUMAN | vasohibin-like protein | Vasohibin-2 | Tubulinyl-Tyr carboxypeptidase 2 | Vasohibin-like protein | Tubulinyl-Tyr carboxypeptidase 2 (isoform 2) | Testicular tissue protein Li 222 | VASH2 variant 2 | Vasohibin 2, transcript variant 2 | Vasohibin 2, transcript variant 1 | testicular tissue protein Li 222 | Tubulinyl-Tyr carboxypeptidase 2 (isoform 1) | vasohibin 2 | VASH2 variant 4 | Tubulinyl-Tyr carboxypeptidase 2 (isoform 4) | Vasohibin 2 | VASH2 variant 1

VASOHIBIN 2: A Potential Drug Target for Cellular Processes

Vasohibin 2 (VASH2) is a protein that is expressed in various tissues throughout the body, including the heart, lungs, kidneys, and intestines. It is a member of the evolutionarily conserved HSP70 protein family and has been implicated in a number of cellular processes, including cell signaling, DNA replication, and stress responses. In this article, we will explore the potential implications of VASH2 as a drug target and the research that has been conducted to study its function.

Drug Target Potential

VASH2 has been identified as a potential drug target due to its involvement in a number of cellular processes that are associated with a variety of diseases, including heart disease, cancer, and neurodegenerative diseases. One of the key reasons for the potential of VASH2 as a drug target is its ability to modulate the activity of multiple cellular signaling pathways, including those involved in cell growth, apoptosis, and angiogenesis.

For example, studies have shown that VASH2 can inhibit the activity of the TGF-β pathway, a signaling pathway that is involved in cell growth, differentiation, and survival. This suggests that VASH2 may have potential as a drug for diseases that are characterized by uncontrolled cell growth, such as cancer.

Another potential mechanism by which VASH2 may be targeted as a drug is its role in the regulation of cell apoptosis, or cell death. Studies have shown that VASH2 can induce apoptosis in a variety of cell types, including cancer cells, and that this may be a potential mechanism by which VASH2 could be used to treat certain forms of cancer.

In addition to its potential role in cell apoptosis, VASH2 has also been shown to be involved in the regulation of cell signaling pathways that are involved in neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. This suggests that VASH2 may have potential as a drug for these diseases.

Biomarker Potential

In addition to its potential as a drug target, VASH2 may also be a useful biomarker for a variety of diseases. For example, studies have shown that VASH2 is expressed in the brains of individuals with Alzheimer's disease, and that levels of VASH2 are decreased in the brains of individuals with this disease. This suggests that VASH2 may be a potential biomarker for Alzheimer's disease and that research into its role in this disease may be valuable.

Another potential application of VASH2 as a biomarker is its involvement in the regulation of cellular stress responses. Studies have shown that VASH2 is involved in the regulation of cellular stress responses, and that this may be a potential mechanism by which VASH2 could be used to treat stress-related diseases.

Discovery and Development of VASH2 as a Drug Target

The discovery and development of VASH2 as a drug target is an active area of research, and there is ongoing interest in studying its potential as a therapeutic agent. One of the key challenges in this field is the development of techniques for specifically targeting VASH2 and modulating its activity, rather than unintended consequences.

One approach that is being explored for the discovery and development of VASH2 as a drug target is the use of small molecule inhibitors. These inhibitors can be designed to specifically bind to VASH2 and inhibit its activity, rather than having unintended effects on other cellular processes.

Another approach that is being explored is the use of antibodies to target VASH2. antibodies are proteins that are designed to recognize and bind to specific molecules, and they can be used to either activate or inhibit the activity of VASH2.

In addition to these approaches, there is also

Protein Name: Vasohibin 2

Functions: Tyrosine carboxypeptidase that removes the C-terminal tyrosine residue of alpha-tubulin, thereby regulating microtubule dynamics and function (PubMed:29146869). Critical for spindle function and accurate chromosome segregation during mitosis since microtuble detyronisation regulates mitotic spindle length and postioning (PubMed:31171830). Acts as an activator of angiogenesis: expressed in infiltrating mononuclear cells in the sprouting front to promote angiogenesis (PubMed:19204325). Plays a role in axon formation (PubMed:31235911)

More Common Targets

VASN | Vasoactive intestinal polypeptide receptor (VIP-R) | Vasohibin | Vasopressin Receptor | Vasopressin V1 Receptor | VASP | VAT1 | VAT1L | VAV1 | VAV2 | VAV3 | VAV3-AS1 | VAX1 | VAX2 | VBP1 | VCAM1 | VCAN | VCL | VCP | VCPIP1 | VCPKMT | VCX | VCX2 | VCX3A | VCX3B | VCY | VCY1B | VDAC1 | VDAC1P2 | VDAC1P9 | VDAC2 | VDAC2P5 | VDAC3 | VDR | VEGFA | VEGFB | VEGFC | VEGFD | VENTX | VENTXP1 | VENTXP7 | VEPH1 | VEZF1 | VEZT | VGF | VGLL1 | VGLL2 | VGLL3 | VGLL4 | VHL | VIL1 | VILL | VIM | VIP | VIPAS39 | VIPR1 | VIPR1-AS1 | VIPR2 | VIRMA | VIT | VKORC1 | VKORC1L1 | VLDLR | VLDLR-AS1 | VMA21 | VMAC | VMO1 | VMP1 | VN1R1 | VN1R101P | VN1R108P | VN1R10P | VN1R11P | VN1R12P | VN1R17P | VN1R18P | VN1R2 | VN1R4 | VN1R46P | VN1R5 | VN1R82P | VN1R91P | VN1R96P | VN2R11P | VN2R1P | VN2R3P | VNN1 | VNN2 | VNN3P | Voltage-dependent anion channels (Porins) | Voltage-dependent calcium channel gamma subunit | Voltage-gated K(v) channel | Voltage-Gated Sodium Channel Complex | Volume-Regulated Anion Channel (VRAC) | VOPP1 | VOR Complex | VPREB1 | VPREB3 | VPS11 | VPS13A